LEGAL AND COMMERCIAL PROTECTION
Patents held by MEDSENIC
Patents on arsenic trioxide in the treatment of autoimmune diseases
The CNRS has granted MEDSENIC an exclusive license to use its family of patents for the use of Arsenic Trioxide in the treatment of autoimmune diseases.
A 10-year extension
The European Medicine Agency (EMA) has granted ODD (Orphan Drug Designation) status to the use of Arsenic Trioxide for the treatment of cGvHD. This recognition will enable MEDSENIC to benefit from an industrial and commercial protection extended by 10 years compared to the initial duration of its CNRS patents, giving it time to complete its clinical studies.
Counterfeit Warnings
Counterfeiting of medicines is a serious crime and represents a significant public health risk.
Counterfeiting can involve impurities, contaminants or incorrect dosing of substances, which can lead to serious health problems and even death.
At MEDSENIC, we take proactive steps to strengthen the quality and safety of our treatments and continue to explore and implement new strategies to prevent counterfeiting and ensure safe and appropriate access to our therapies.